Higher adherence during reimbursement of pharmacological smoking cessation treatments

Nicotine and Tobacco Research

Volumn 18, Issue 1, 2016, Pages 56-63

  van Boven, Job F M ^a   Vemer, Pepijn ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; VARENICLINE; NICOTINE GUM;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; SMOKING CESSATION; TOBACCO DEPENDENCE; COUNSELING; ECONOMICS; MIDDLE AGED; NETHERLANDS; PREVENTION AND CONTROL; PROCEDURES; PSYCHOLOGY; SMOKING;

ADULT; BUPROPION; COUNSELING; FEMALE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; VARENICLINE;

EID: 84954515618     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntv064     Document Type: Article

References (42)

1. Muller F, Wehbe L. Smoking and smoking cessation in Latin America: a review of the current situation and available treatments. Int J Chron Obstruct Pulmon Dis. 2008;3(2):285-293. doi:10.2147/COPD.S2654.
2. Raupach T, van Schayck CP. Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs. 2011;25(5):371-382. doi:10.2165/11590620-000000000-00000.
3. Wacker M, Holle R, Heinrich J, et al. The association of smoking status with healthcare utilisation, productivity loss and resulting costs: results from the population-based KORA F4 study. BMC Health Serv Res. 2013;13:278. doi:10.1186/1472-6963-13-278.
4. Tremblay M, Payette Y, Montreuil A. Use and reimbursement costs of smoking cessation medication under the Quebec public drug insurance plan. Can J Public Health. 2009;100(6):417-420. http://journal.cpha.ca. Accessed 21 August 2014.
5. Lutsenko H, Doran CM, Hall WD. Australian smokers' use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05. Drug Alcohol Rev. 2008;27(2):160-164. doi:10.1080/09595230701829462.
6. Chang FC, Hu TW, Lin M, Yu PT, Chao KY. Effects of financing smoking cessation outpatient services in Taiwan. Tob Control. 2008;17(3):183-189. doi:10.1136/tc.2007.021907.
7. Verbiest ME, Chavannes NH, Crone MR, et al. An increase in primary care prescriptions of stop-smoking medication as a result of health insurance coverage in the Netherlands: population based study. Addiction. 2013;108(12):2183-2192. doi:10.1111/add.12289.
8. Willemsen MC, Segaar D, van Schayck OC. Population impact of reimbursement for smoking cessation: a natural experiment in The Netherlands. Addiction. 2013;108(3):602-604. doi:10.1111/j.1360-0443.2012.04089.x.
9. Reda AA, Kotz D, Evers SM, van Schayck CP. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev. 2012;6:CD004305. doi:10.1002/14651858. CD004305.pub4.
10. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax. 2010;65(8):711-718. doi:10.1136/thx.2009.131631.
11. Nohlert E, Helgason AR, Tillgren P, Tegelberg A, Johansson P. Comparison of the cost-effectiveness of a high-and a low-intensity smoking cessation intervention in Sweden: a randomized trial. Nicotine Tob Res. 2013;15(9):1519-1527. doi:10.1093/ntr/ntt009.
12. Salize HJ, Merkel S, Reinhard I, Twardella D, Mann K, Brenner H. Costeffective primary care-based strategies to improve smoking cessation: more value for money. Arch Intern Med. 2009;169(3):230,5; discussion 235-6. doi:10.1001/archinternmed.2008.556.
13. Vemer P, Rutten-van Molken MP. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health. 2010;13(2):230-241. doi:10.1111/j.1524-4733.2009.00612.x.
14. Vemer P, Rutten-van Molken MP, Kaper J, Hoogenveen RT, van Schayck CP, Feenstra TL. If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands. Addiction. 2010;105(6):1088-1097. doi:10.1111/j.1360-0443.2010.02901.x.
15. Menzin J, Lines LM, Marton J. Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right? Expert Rev Pharmacoecon Outcomes Res. 2009;9(3):257-264. doi:10.1586/erp.09.28.
16. Salize HJ. Commentary on Vemer et al. (2010): when is smoking cessation really cost-effective? Addiction. 2010;105(6):1098-1099. doi:10.1111/j.1360-0443.2010.02967.x.
17. World Health Organization. Adherence to Long-Term Therapies-Evidence for Action. 2003. http://apps.who.int/medicinedocs/pdf/s4883e/s4883e.pdf. Accessed 20 August 2014.
18. Mooney ME, Sayre SL, Hokanson PS, Stotts AL, Schmitz JM. Adding MEMS feedback to behavioral smoking cessation therapy increases compliance with bupropion: a replication and extension study. Addict Behav. 2007;32(4):875-880. doi:S0306-4603(06)00202-4.
19. Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res. 2010;12(6):574-581. doi:10.1093/ntr/ntq047.
20. Catz SL, Jack LM, McClure JB, et al. Adherence to varenicline in the COMPASS smoking cessation intervention trial. Nicotine Tob Res. 2011;13(5):361-368. doi:10.1093/ntr/ntr003.
21. Balmford J, Borland R, Hammond D, Cummings KM. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res. 2011;13(2):94-102. doi:10.1093/ntr/ntq215.
22. Raupach T, Brown J, Herbec A, Brose L, West R. A systematic review of studies assessing the association between adherence to smoking cessation medication and treatment success. Addiction. 2014;109(1):35-43. doi:10.1111/add.12319.
23. Chavannes NH, Kaper J, Frijling BD, et al. NHG-Standaard Stoppen met roken [in Dutch]. Huisarts Wet. 2007;50(7):306-314. www.nhg.org/standaarden/samenvatting/stoppen-met-roken. Accessed 20 August 2014.
24. Zeng F, Chen CI, Mastey V, Zou KH, Harnett J, Patel BV. Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims. Clin Ther. 2011;33(2):225-234. doi:10.1016/j.clinthera.2011.02.013.
25. Suehs BT, Davis C, Galaznik A, Joshi AV, Zou KH, Patel NC. Association of out-of-pocket pharmacy costs with adherence to varenicline. J Manag Care Pharm. 2014;20(6):592-600.
26. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2014. www.whocc.no/atcddd.2014. Accessed 14 August 2014.
27. Visser ST, Schuiling-Veninga CC, Bos JH, de Jong-van den Berg LT, Postma MJ. The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):285-292. doi:10.1586/erp.13.20.
28. Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S. Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. Osteoporos Int. 2014;25(6):1807-1812. doi:10.1007/s00198-014-2659-8.
29. van Boven JF, van Raaij JJ, van der Galien R, et al. Impact of multipledose versus single-dose inhaler devices on COPD patients' persistence with long-acting beta(2)-agonists: a dispensing database analysis. NPJ Prim Care Respir Med. 2014;24:14069. doi:10.1038/npjpcrm.2014.69.
30. Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S. Proactive pharmaceutical care interventions improve patients' adherence to lipidlowering medication. Ann Pharmacother. 2013;47(11):1448-1456. doi:10.1177/1060028013501146.
31. van Boven JF, de Boer PT, Postma MJ, Vegter S. Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab. 2013;31(5):562-570. doi:10.1007/s00774-013-0440-2.
32. Liberman JN, Lichtenfeld MJ, Galaznik A, et al. Adherence to varenicline and associated smoking cessation in a community-based patient setting. J Manag Care Pharm. 2013;19(2):125-131.
33. Kaper J, Wagena EJ, Willemsen MC, van Schayck CP. A randomized controlled trial to assess the effects of reimbursing the costs of smoking cessation therapy on sustained abstinence. Addiction. 2006;101(11):1656-1661. doi:10.1111/j.1360-0443.2006.01578.x.
34. Schuck K, Bricker JB, Otten R, Kleinjan M, Brandon TH, Engels RC. Effectiveness of proactive quitline counselling for smoking parents recruited through primary schools: results of a randomized controlled trial. Addiction. 2014;109:830-841. doi:10.1111/add.12485.
35. Bock BC, Papandonatos GD, de Dios MA, et al. Tobacco cessation among low-income smokers: motivational enhancement and nicotine patch treatment. Nicotine Tob Res. 2014;16(4):413-422. doi:10.1093/ntr/ntt166.
36. Public Health and Smoking Foundation (STIVORO). How Many Dutch People Smoke? www.rokeninfo.nl/publiek/cijfers/hoeveel-mensen-roken. Accessed 17 October 2014.
37. Nagelhout GE, Hummel K, Willemsen MC, et al. Are there income differences in the impact of a national reimbursement policy for smoking cessation treatment and accompanying media attention? Findings from the International Tobacco Control (ITC) Netherlands Survey. Drug Alcohol Depend. 2014;140:183-190. doi:10.1016/j. drugalcdep.2014.04.012.
38. Buchanan TS, Berg CJ, Cox LS, et al. Adherence to varenicline among African American smokers: an exploratory analysis comparing plasma concentration, pill count, and self-report. Nicotine Tob Res. 2012;14(9):1083-1091. doi:10.1093/ntr/ntr333.
39. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011. doi:10.1002/14651858.CD000011.pub3.
40. van Baal PH, Brouwer WB, Hoogenveen RT, Feenstra TL. Increasing tobacco taxes: a cheap tool to increase public health. Health Policy. 2007;82(2):142-152. doi:S0168-8510(06)00192-8.
41. Bock BC, Hudmon KS, Christian J, Graham AL, Bock FR. A tailored intervention to support pharmacy-based counseling for smoking cessation. Nicotine Tob Res. 2010;12(3):217-225. doi:10.1093/ntr/ntp197.
42. Schmitz JM, Sayre SL, Stotts AL, Rothfleisch J, Mooney ME. Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback. J Behav Med. 2005;28(2):139-147. doi:10.1007/s10865-005-3663-4.